Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 27.07.2021 at 12:00 PM CEST
Settings

Settings

Goto Application

1. WO2002045734 - TAHITIAN NONI JUICE ON COX-1 AND COX-2 AND TAHITIAN NONI JUICE AS A SELECTIVE COX-2 INHIBITOR

Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

[ EN ]

1. A method of treating pain and inflammation comprising the steps of providing a dose of Morinda citrifolia for consumption and
limiting undesired COX-1 inhibition relative to COX-2 inhibition by limiting the concentration of said dose.

2. The method of claim 1 , wherein the Morinda citrifolia is processed.

3. The method of claim 1 , wherein the Morinda citrifolia is in liquid form.

4. The method of claim 1, wherein the Morinda citrifolia is included as an ingredient in a food product.

5. The method of claim 1, wherein the Morinda citrifolia is in capsule form.

6. The method of claim 1, wherein said dose of Morinda citrifolia inhibits the production of COX-2 related prostaglandins that cause pain and inflammation and inhibits to a lesser extent, the production of COX-1 related prostaglandins.

7. The method of claim 1 , wherein said dose of Morinda citrifolia is administered at a predetermined concentration.

8. The method of claim 7, wherein said Morinda citrifolia is included as an ingredient in another food product.

9. A method of treating pain and inflammation comprising the steps of: obtaining a quantity of Morinda citrifolia juice and pulp; filtering the wet pulp from the juice;
pasteurizing the juice; and
providing a dose of said Morinda citrifolia juice for consumption.

10. The method of claim 9, wherein the Morinda citrifolia juice is included as an ingredient in a food product.

11. The method of claim 9, wherein said dose is administered in an amount that is pre-determined to limit undesired COX-1 inhibition relative to COX-2 inhibition.

12. A method of treating pain and inflammation comprising the steps of: obtaining a quantity of Morinda citrifolia juice and pulp; filtering the wet pulp from the juice, wherein the wet pulp has a fiber content of from 10% to 40%, by weight;
pasteurizing the pulp; and
providing a therapeutic dose of said Morinda citrifolia pulp for consumption.

13. The method of claim 12, wherein the Morinda citrifolia pulp is included as an ingredient in a food product

14. The method of claim 12, wherein said dose is administered in an amount that is pre-determined to limit undesired COX-1 inhibition relative to COX-2 inhibition.